![CAS:950769-58-1 N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea](/npublic/img/s.png "CAS:950769-58-1 N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea")
CAS:950769-58-1 N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea
NAME:N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea CAS:950769-58-1 MF:C29H32N6O4S MW:560.67 PURITY:98%
Categories：
Material Chemistry
Email：sale06@alfachem.cn
Product introduction
| NAME | N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea |
| CAS | 950769-58-1 |
| MF | C29H32N6O4S |
| MW | 560.67 |
| DENSITY | 1.39±0.1 g/cm3 |
| STORAGE | -20°C |
Description
Quizartinib, also known as AC220 or Vanflyta, is an oral, highly potent, and selective next-generation FLT3 inhibitor . It is used in combination with other medicines (e.g., cytarabine, anthracycline) and alone as maintenance therapy to treat acute myeloid leukemia in patients with a FLT3-ITD mutation . It was approved for medical use in Japan in October 2019, in the United States in July 2023, and the European Union in November 2023 .
Key words:
Related Products
Related Products
Inquiry
Phone/WhatsApp:
Email:
Through its excellent service and product qualities, VT Chemical has cooperated with many famous customers all over the world, eg. TCI, Covestro, etc.
HUATAO GROUP
Leave Message
SAF Coolest v1.3.1.2 设置面板 MFBSX-AJYI-DZAAE-ZAQ
无数据提示
Sorry, the current column is being updated, please look forward to it!
You can view other columns